TrialBlood2013

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

Stephen H Petersdorf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.